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The ability to resist complement differs between the Y and ColombianaTrypanosoma cruzi strains. We found that
the Y strain of T. cruziwas more able to resist the classical and lectin pathways of complement activation than the
Colombiana strain. The complement C2 receptor inhibitor trispanning gene (CRIT) is highly conserved in both
strains. At the protein level, CRIT is expressed only in stationary-phase epimastigotes of the Y but not the Colom-
biana strain and is expressed in infectious metacyclic trypomastigotes of both strains. Y strain epimastigotes with
an overexpressedCRITgene (pTEX-CRIT) had higher survival in normal human serum (NHS). Overexpression of
the Y strain CRIT gene in Colombiana epimastigote forms increased the parasite’s resistance to lysis mediated by
the classical and lectin pathways but not to lysis mediated by alternative pathways. CRIT involvement on the
parasite surface was confirmed by showing that the lytic activity of NHS against epimastigotes could be restored by
adding excess C2.
Trypanosoma cruzi is a protozoan parasite that causes
Chagas disease and that affects 18million people in Latin
America, with 90 million at risk of infection worldwide
[1]. Approximately 30%of individuals in the indetermi-
nate stage, in which parasitemia is undetectable and pa-
tients remain asymptomatic, progress to the chronic
stage with severe sequelae, such as cardiomyopathy or
gastrointestinal dysfunction [2, 3].
T. cruzi needs to evade the host innate immune re-
sponse to establish an infection and initiate disease. The
first mechanism of vertebrate host defense against the
parasite is the complement (C) system, which is com-
posed of 30 serum proteins activated in a cascade that
culminates in the lysis of the parasite. There are 3Cpath-
ways leading to pathogen lysis by the membrane attack
complex. The classical pathway (CP), activated by IgG/
IgM binding to pathogen, and the alternative pathway
(AP), activated through C3b binding to pathogen, have
been described. However, there has been little descrip-
tion of lectin pathway (LP) activation in trypanosoma-
tids, via mannan-binding lectin (MBL) binding to car-
bohydrate on the pathogen surface [4–8].
During its life cycle, the parasite undergoes a series of
developmentally regulated morphological and physio-
logical changes to survive within insects and mamma-
lian cells. Thus, vertebrate-stage parasites (blood trypo-
mastigotes and amastigotes) and infective vector-stage
parasites (metacyclic trypomastigotes) typically resist
direct serum killing and can also evade ingestion or in-
tracellular killing by a host phagocyte cell. In contrast,
most noninfective vector-stage parasites (epimastig-
otes) are susceptible to lysis by serum and to phagocyto-
sis and destruction by polymorphonuclear leukocytes.
The membrane changes that control the transforma-
tion of these parasites from being C sensitive to resistant
are only partially understood. Pioneering studies of
C-mediated lysis of trypanosomatids described antibod-
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ies of patients in the chronic phase responsible for CP activation
and parasite killing [4, 6, 9]. Otherwise, the prevailing explana-
tion forC activation during the infection is that parasites activate
lysis through the AP, thereby lacking the involvement of anti-
bodies, despite the deposition of C3b on the trypomastigote par-
asite surface [8] and parasite lysis occurring in the presence of
serum depleted of factors of the AP [9].
Themechanisms displayed byT. cruzi for avoiding the C system
are refined, specificmolecules havingbeen reported asC inhibitors.
Trypanosome decay–accelerating factor has been reported to bind
toCcomponentC3andC-regulatoryprotein tobind toC3andC4,
thereby blocking the CP and AP [10, 11]. Other molecules have
been shown to confer resistance toCP- andAP-mediated lysis, such
as calreticulin, which interacts with C1q and blocks only the CP
[12], as well as gp 58/68, which inhibits the AP [13]. Recently, a
receptor responsible for specific inhibitionofCPactivation inSchis-
tosoma species [14] was described, a homologue of which we re-
cently identified inT. cruzi [15].ComplementC2receptor inhibitor
trispanning (CRIT) is a transmembrane protein of 32 kDa. The
N-terminal first extracellular domain (ed1) of CRIT shows se-
quence homology with part of the C4 -chain and competes for
binding to C2 [16] via its vonWillebrand factor A domain [17]. In
bindingC2,CRITinhibits theC1s-mediatedcleavageofC2.CRITis
highly conserved in Schistosoma species,T. cruzi strains, andmam-
mals [15].
To have an overall understanding of the mechanism of C ac-
tivation inT. cruzi infection,weneed to consider thewide variety
of strains described. On the basis of biological and epidemiolog-
ical data, T. cruzi has been divided into 2 divergent groups or
lineages. T. cruzi class I is found in the sylvatic transmission
cycle, which affects mainly American marsupials and edentates
[18, 19]. As an example of a class I strain, T. cruziColombiana is
used in this study. By contrast, T. cruzi class II is found in the
domestic transmission cycle and affects mainly humans; an ex-
ample of a class II strain, T. cruzi Y strain is used. Several molec-
ular markers allow the classes to be distinguished, such as the
24SrRNA gene, the intergenic region of tandemly repeated
mini-exon gene, microsatellite DNA, and polymerase I pro-
moter activity [19–21]. The physiological relevance of T. cruzi
divergence was recently shown when it was revealed that87%
of patients with Chagas disease have antibodies against the try-
pomastigote small surface antigen of T. cruzi II [22].
Differential expression of C-regulatory genes within the di-
vergent classes of T. cruzi has to date not been linked with the
ability to resist C-mediated lysis. First, we show that C activation
differs between the T. cruzi Y and Colombiana strains, as does
the expression of the CRIT gene, which is expressed in a class-
specificmanner.WefindCRIT protein expressed in the infective
stage of T. cruzi and show that epimastigote transgenic parasites
expressing CRIT are more resistant to C lysis, blocking the CP
and LP.
METHODS
Parasites. T. cruzi epimastigote forms of strains Y andColom-
biana were cultured in liver infusion tryptose (LIT) medium
supplemented with 10% fetal bovine serum at 27°C [23]. Meta-
cyclic forms were obtained and purified as described elsewhere
[23, 24].
C-mediated lysis assay. First, 5.0  105 logarithmic epi-
mastigote forms of T. cruzi were resuspended in 100 L of fresh
RPMI 1640 and mixed with 100 L of diluted normal human
serum (NHS) in RPMI 1640medium at 37°C inmicrocentrifuge
tubes for 30 min. After incubation (30 s to 30 min), 800 L of
cold RPMI 1640 was added, and the tube was placed on ice.
Heat-inactivated NHS (56°C for 30 min) was used as a negative
control. Surviving parasites were stained with trypan blue and
quantified in aNeubauer chamber under a lightmicroscope. For
calculating the serum concentration that causes 50% lysis of par-
asites (serum lethal concentration [SLC]–50), parasites were in-
cubated in 2-fold serial dilutions, ranging from undiluted to
3.12% NHS.
The kinetics of C-mediated killing was determined by incu-
bating parasites in 25%NHS for 0.5, 1, 2.5, 5, 10, and 30min. CP
and LP inhibition were performed by incubating NHS with 10
mmol/L ethylene glycol tetraacetic acid (EGTA) and 7 mmol/L
MgCl2.
C-mediated lysis was assayed using transgenic (pTEX and
pTEX-CRIT) and wild-type parasites from the T. cruzi Y and
Colombiana strains. Parasites growing in LITmedium (with 200
g/mL G418 added for transgenic parasite culture) at logarith-
mic phase (3 days) were used in this experiment.T. cruziY strain
parasites were incubated with 25% NHS, whereas Colombiana
strain parasites were incubated with 12.5% NHS. In certain ex-
periments in which 0.5 g of C2 (0.02 mol/L) was added to
restore the lysis of pTEX-CRIT transgenic parasites, kinetics
were realized with 25% NHS (CP, LP, and AP activation).
Gene cloning and sequencing. Oligonlucleotides (5'-CCCG-
GATTCATGTACGGGCCAGATAT-3' [forward] and 5'-CCC-
AAGCTTTTAATTTCGATAAGCCAGT-3' [reverse]) based on
CRITDNA sequences from Schistosomamansoni (GenBank acces-
sion number 6650015) were used to amplify a 0.85-kb fragment
from T. cruzi Y strain genomic DNA by polymerase chain reaction
(PCR). The PCR product was cloned into pGEM-T Easy Vector
(Promega) and sequenced with T7 and T3 oligonucleotides using
anABI 3100 automatedDNAsequencer. The sequenceofT. cruziY
strain was deposited in GenBank (accession no. AY464185). The
genes of T. cruzi Cl Brener, Colombiana, and Dm28c were ampli-
fied by PCR from genomic DNA using oligonucleotides (5'-
ATGTCTCCAAGTCTAGTG-3' [forward] and 5'-TTAACAAG-
AAGAGTGAG-3' [reverse]) based on the CRIT sequence of the T.
cruzi Y strain (GenBank accession nos. AF212030, AF212031, and
AF212029, respectively).
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Constructions and transfections. The CRIT gene from the
Y strain cloned into pGEM-T Easy Vector was digested with
EcoRI and subcloned into the trypanosomatid expression vector
pTEX, generating the vector pTEX-CRIT. Twenty-five micro-
grams of pTEX and pTEX-CRIT was used to transfect epimas-
tigote forms of T. cruzi Y and Colombiana strains in logarithmic
phase by an electroporation method described elsewhere [21].
Western blotting. Parasites were washed in PBS, adjusted to
5.0  106 parasites/L, and lysed with 0.1% Triton X-100/PBS/
protease inhibitor cocktails, as described elsewhere [13]. In brief,
after SDS-PAGE and transfer to nitrocellulose, the primary an-
tibody used was affinity-purified rabbit anti–CRIT-ed1 (1:100),
as described elsewhere [14]. Immunoabsorption was performed
by preincubating the anti–CRIT-ed1 with synthetic peptide ed1
[16] before incubation with the membrane.
Fluorescence-activated cell sorter (FACS) analysis. T. cruzi
metacyclic trypomastigotes (2.0  105 parasites) were incubated
with 1 g of C2 for 1 h at 4°C. After that, parasites were washed
2 times with PBS and incubated with fluorescein isothiocyanate
(FITC)–conjugated anti-C2 antibody, diluted 1:10 in PBS–1%
bovine serum albumin, for 2 h at 4°C. IgG-FITC was used as an
isotype control. Parasites were thenwashed 3 times and analyzed
by flow cytometry using theGuava EasyCyte ExpressPlus System
(Guava Technologies).
Data presentation and statistical analysis. All data are
shown asmeans SDs. Groups were compared by the unpaired
t test for repeated measures, using Prism software (version 5.0;
GraphPad). Differences were considered statistically significant
at P  .05 with a confidence interval of 99%.
RESULTS
Greater susceptibility of the T. cruzi Colombiana strain than the
Y strain to C-mediated lysis in the presence of NHS. Assays of
C-mediated lysis were performed on epimastigote forms ofT. cruzi
Colombiana and Y strains, grown to the logarithmic phase, with
serial dilutions of NHS to determine the serum concentration that
causes SLC-50 in 30min at 37°C.
T. cruzi Y strain epimastigote forms were lysed with NHS at
concentrations of 6.25% and above, and the SLC-50 was be-
tween 25% and 50%. However, the Colombiana strain needed
only as little as 3.12% NHS, and the SLC-50 was between 6.25%
and 12.5% (figure 1). T. cruziColombiana was more susceptible
toC lysis thanT. cruziY at all serum concentrations, being 8-fold
more lysed than the Y strain at 25% NHS.
The kinetics of C pathway–mediated lysis in T. cruzi Co-
lombiana and Y strains. The kinetics of C-mediated lysis with
NHS (CP, LP, and AP) and EGTA-treated NHS (evaluating only
the AP, a calcium-independent process) showed differing de-
Figure 1. Determination of the serum concentration that causes 50%
lysis of parasites. Trypanosoma cruzi Y and Colombiana strains were
incubated in several concentrations of normal human serum (NHS) for 30
min at 37°C. Bars represent the SDs of 3 individual experiments per-
formed in triplicate. The results are significantly different at 6.25%,
12.5%, 25%, and 50% NHS (P  .05).
Figure 2. Kinetics of complement activation. A, Trypanosoma cruzi Y
and Colombiana strains incubated with 25% normal human serum (NHS)
at 37°C for 0.5–30 min. B, T. cruzi Y and Colombiana strains incubated
with 25% NHS treated with 10 mmol/L ethylene glycol tetraacetic acid
and 7 mmol/L MgCl2 for 0.5–30 min. Bars represent SDs of 3 individual
experiments performed in triplicate. In panel A, results are significantly
different at 2.5 and 5 min; in panel B, results are significantly different
at 5 and 30 min (P  .05).
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grees of resistance in the T. cruzi Y and Colombiana strains (fig-
ure 2A and 2B). TheT. cruziColombiana and Y strains exhibited
a divergence in lysis after 1 min of incubation with NHS, and at
2.5 and 5 min the survival levels of Colombiana strains were
significantly lower (figure 2A) than for T. cruzi Y strain. After 10
min, the Colombiana strain was totally lysed; with the Y strain,
17.4%of parasites survived, these being totally lysed only after 30
min (figure 2A). Alternatively, when kinetic assays were per-
formed in the presence of AP alone, both parasites survived up to
30 min of lysis (figure 2B). After 2.5 and 5 min the Colombiana
strain showed 68% and 56% survival, respectively, where the Y
strain showed significantly higher levels after the same intervals
(90% and 78% survival, respectively) (figure 2B).
Cloning of CRIT, inhibitor of the CP and LP, in T. cruzi
strains. Having described a C2 inhibitory receptor, CRIT [13,
15], in S. mansoni and Schistosoma haematobium parasites, we
used oligonucleotides based on S. haematobiumCRIT sequences
to amplify from the genomic DNA of the T. cruzi Y strain. The
PCR product was amplified and cloned into the pGEM-T Easy
Vector for sequencing. The sequence shares a high nucleotide
similarity with CRIT described in Schistosoma species. BLAST
analysis at the amino acid level showed similarities of 97% and
96% with S. mansoni and S. haematobium CRIT, respectively
[15].
The CRIT gene was also amplified by PCR from genomic
DNAofT. cruzi strains Cl Brener, Colombiana, andDm28c. The
PCR fragments were sequenced and found to share a high simi-
larity with CRIT from the T. cruzi Y strain, Schistosoma species,
and mammals. At the amino acid level, the similarity between
CRIT from T. cruzi Cl Brener, Colombiana, and Dm28c strains
compared with T. cruzi Y strains was 90% (figure 3A). The
CRIT sequences reveal in the N-terminal region an ed1 domain
of 27 residues and in the C-terminal region (residues 224–274) a
serine-threonine–rich region. The ed1 (figure 3A) was shown to
bind to C factor C2 and inhibit CP activation [16]. CRIT does
not have an N-terminal signal peptide and possesses 3 highly
hydrophobic regions predicted to form transmembrane helices
that could be integrated into the parasite membrane. The pre-
dicted topology of all the CRIT proteins remains that of a type
IIIb membrane protein [25] with an extracellular N-terminus
and cytoplasmic C-terminal tail. All of the T. cruzi strains have
an identical ed1 (figure 3B). Searching various sequence data-
bases reveals that the cytoplasmic tail of CRIT (mammalian par-
asite) has homology with similar regions in receptors that are
endocytosed or that have a lysosomal targeting sequence, as
highlighted elsewhere [26].
Differential expression of CRIT in T. cruzi Y and Colom-
biana strains. The expression of CRIT in T. cruzi Y and Co-
Figure 3. A, Similarity analysis of complement C2 receptor inhibitor trispanning (CRIT) amino acid sequences from Trypanosoma cruzi Y, Colombiana,
Cl Brener, and Dm28c strains. The alignment was done using the ClustalW tool. Asterisks indicate identical amino acids, dots indicate related amino
acids, the box indicates the 27-aa sequence of extracellular domain 1 (ed1) in the N-terminal region, bars indicate the serine-threonine–rich region in
the C-terminal region (amino acid positions 224 –274), and dotted lines indicate hydrophobic regions. B, Comparison of the 27 aa that comprise the ed1
of CRIT from various species. Shaded areas indicate where amino acids differ between the species.
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lombiana strains was analyzed during the in vitro differentiation
from epimastigote to metacyclic trypomastigote forms. Immu-
noblotting using anti–CRIT-ed1 (which is specific for the
N-terminal domain ed1 of CRIT) showed expression inmetacy-
clic trypomastigote forms of both strains and in stationary- but
not logarithmic-phase epimastigote forms of T. cruzi Y strain
(figure 4). CRIT was detected as a protein of 27–32 kDa, com-
pared with the already-described 32-kDa CRIT protein in Schis-
tosoma species and mammals, and this signal could be removed
by adsorption of the antibody with CRIT-ed1 peptide. Apart
fromahomology [16] to part of theC4-chain, which is 78 kDa,
the CRIT-ed1 sequence is quite specific to the CRIT family of
proteins.
Resistance to C-mediated lysis conferred by overexpression
of CRIT in the epimastigote form of T. cruzi. To understand
the role that CRIT plays in providing resistance to C-mediated
lysis inT. cruzi, theCRIT gene of the Y strain was cloned into the
pTEX expression vector and overexpressed in logarithmic epi-
mastigote forms of theT. cruzi Y and Colombiana strains (figure
4B). The overexpressedCRIT gene in Y andColombiana confers
an increased resistance to C-mediated lysis in NHS compared
with wild-type parasites. The transgenic parasites were assayed
for their ability to resist C-mediated lysis by monitoring the ki-
netics of lysis.T. cruziY strainwas incubatedwith 25%NHS, and
within 5 and 10min a differencewas detected in lysis (figure 5A).
Transgenic parasites (pTEX-CRIT), after 5 min of incubation
with serum, showed equal numbers of survivors, with pTEX and
wild-type parasites. After 10 min, wild-type and pTEX trans-
genic parasites had significantly fewer survivors than pTEX-
CRIT transgenic strains. When these parasites were incubated
with 25% NHS treated with EGTA and MgCl2 to inhibit the CP
and LP (figure 5B), the transgenic (pTEX-CRIT), pTEX, and
Figure 4. Western blotting of Trypanosoma cruzi Y and Colombiana
strains. In panel A, total protein extracts were obtained from epimastig-
otes of logarithmic- and stationary-phase and from metacyclic-form par-
asites with Triton X-100 (1% in PBS). The membrane was incubated with
affinity-purified anti–CRIT-ed1 polyclonal antibody. Immunoabsorption
was done with extracellular domain 1 (ed1) peptide to block the binding
of the antibody to complement C2 receptor inhibitor trispanning (CRIT)
protein. In panel B, total protein extracts from wild-type, pTEX, and
pTEX-CRIT transfectants of T. cruzi Y and Colombiana strains were
obtained similarly and probed with antibody, as in panel A.
Figure 5. Complement lysis assay comparing the resistance to lysis of
Trypanosoma cruzi Y strain wild-type (wt), transgenic pTEX, and pTEX–
complement C2 receptor inhibitor trispanning (CRIT) parasites. A, Kinetics
realized with 25% normal human serum (NHS) (classical, lectin, and
alternative pathway activation) over a time course of 2.5–30 min at 37°C.
B, Kinetics realized with 25% NHS treated with 10 mmol/L ethylene
glycol tetraacetic acid and 7 mmol/L MgCl2 (alternative pathway activa-
tion only) over a time course of 2.5– 60 min at 37°C. Bars represent SDs
of single individual experiments performed in triplicate. In panel A,
results are significantly different at 10 min comparing pTEX-CRIT with wt
and with pTEX transgenic parasites (P  .05). In panel B, results are not
significantly different comparing pTEX-CRIT with wt and with pTEX
transgenic parasites.
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wild-type strains were lysed to a similar extent. This indicates
that CRIT inhibits the CP and the LP but does not confer resis-
tance toAP-mediated lysis. The overexpression of theCRIT gene
of theT. cruziY strain in theT. cruziColombiana strain was thus
able to confer resistance to C-mediated lysis byNHS. Incubation
of Colombiana strain expressing pTEX-CRIT with 12.5% NHS
after 7.5 min showed that transgenic parasites were 2-fold more
resistant (2.43  105 surviving parasites [49%]) comparedwith
wild-type parasites (1.28  105 surviving parasites [26%]) (fig-
ure 6). These data indicate that the CRIT of Y strain was func-
tional in the Colombiana strain and that the difference in the
susceptibility to lysis by Cmay be associated with the differential
expression of specific molecules present in each strain.
Restoration of the susceptibility to lysis by exogenous C2 in
transgenic parasites overexpressing CRIT. The ability of over-
expressedCRIT in epimastigoteY strain to resistC-mediated lysis is
directly related to C2 binding to CRIT on the parasite surface and
depletionof availableC2 fromNHS.Weperformed experiments in
which C2 added to NHS restored its ability to lyse epimastigotes.
With the addition of 0.5g of C2 (0.02mol/L), the 65% survival
rate of transgenic parasites (pTEX-CRIT) was reduced to 43%,
comparable with the survival levels of pTEX epimastigotes (para-
sites transfected with vector alone) and wild-type parasites (figure
7A). Furthermore,C2binding to the infectivemetacyclic trypomas-
tigote form ofT. cruziwas confirmed by FACS analysis (figure 7B).
Figure 6. Complement lysis assay comparing the resistance to lysis of
Trypanosoma cruzi Colombiana strain wild-type (WT), transgenic pTEX,
and pTEX– complement C2 receptor inhibitor trispanning (CRIT) parasites.
A, Kinetics realized with 12.5% normal human serum (NHS) (classical,
lectin, and alternative pathway activation) over a time course of 2.5–30
min at 37°C. B, Kinetics realized with 12.5% NHS treated with 10 mmol/L
ethylene glycol tetraacetic acid and 7 mmol/L MgCl2 (alternative pathway
activation only) over a time course of 2.5–30 min at 37°C. Bars represent
SDs of single individual experiments performed in triplicate. In panel A,
results are significantly different at 5 and 7.5 min comparing pTEX-CRIT
with WT and with pTEX transgenic parasites (P  .05). In panel B,
results are not significantly different comparing pTEX-CRIT with WT and
with pTEX transgenic parasites.
Figure 7. Complement lysis assay showing restoration of the lysis of
pTEX– complement C2 receptor inhibitor trispanning (CRIT) transgenic
parasites via added C2. A, Kinetics realized with 25% normal human
serum (NHS) (classical, lectin, and alternative pathway activation) with
wild-type (WT), transgenic pTEX, and pTEX-CRIT of Trypanosoma cruzi Y
strain. The NHS was restored with 0.5 g of C2. The reaction was
incubated at 37°C over a time course of 2.5–30 min. Results are
significantly different at 2.5, 5, and 10 min comparing pTEX-CRIT with
both WT and pTEX-CRIT transgenic parasites (P  .05); results are not
significantly different comparing pTEX-CRIT (with added C2) with WT or
pTEX transgenic parasites (both with added C2). B, Binding of C2 to
metacyclic trypomastigote forms of T. cruzi. Parasites (2.0  105) were
incubated with C2 for 1 h at 4°C followed by incubation with fluorescein
isothiocyanate (FITC)– conjugated anti-C2 antibody. Analysis was done by
flow cytometry using the Guava EasyCyte ExpressPlus System (Guava
Technologies). IgG-FITC was used as an isotype control.
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DISCUSSION
We have shown that the Colombiana and Y strains of T. cruzi,
which belong to the 2 phylogenetic lineages class I and class II,
respectively, differ in their capacity to resist C-mediated lysis,
andwe attribute this in part to the expression ofCRIT. It was also
our aim to investigate the expression of CRIT in epimastigote
forms as they differentiate into infectivemetacyclic trypomastig-
otes.
Complement lysis assays showed that theT. cruziColombiana
strain is more susceptible to lysis than the T. cruzi Y strain at all
serum concentrations. Kinetic assays were then performed to
ascertain to which pathways strains were resistant. After 2.5 and
5 min in the presence of all 3 pathways, the Colombiana strain
showed survival levels of 11% and 2.6%, respectively, whereas
the Y strain presented survival levels of 60% and 44.6%, respec-
tively. However, when the kinetic assays were performed with
EGTA-treated NHS, which blocked the CP and the LP, lysis was
slow to occur and had similar levels between the strains, with
survival still being maintained for up to 30 min. Thus, the Co-
lombiana strain’s greater susceptibility to C lysis appears to be
mainly due to the CP and LP in early activation. These findings
are in accordance with those of similar experiments in Leishma-
nia species and Crithidia species [27], which showed a rapid
activation of the CP. Additionally, the involvement of the AP,
supposed to be the first mechanism in C-mediated lysis in T.
cruzi [7, 8, 28], showed a minimum role in immediate lysis.
As a mechanism of C-mediated lysis in T. cruzi, which is im-
portant during the early activation of C, the LP [29, 30] has been
little considered. However, in Leishmania braziliensis it was re-
cently shown that MBL binds to surface glycoconjugates and
activates the LP [5]. SA85–1, amannose receptor found in amas-
tigote forms of T. cruzi, binds to MBL and is involved in the
uptake of the parasites into macrophages, thus increasing infec-
tion [31]. Recently, it was reported that MBL deficiency in pa-
tients increases susceptibility to infection [32, 33].
The switch by which trypanosomatids have evolved from the
epimastigote form, which is sensitive to C-mediated lysis by
NHS, to the C-resistant metacyclic form is not well understood.
Norris [11] showed that aC3 receptor, C-regulatory protein, was
expressed in trypomastigote forms and not in insect-stage epi-
mastigotes. The overexpression of the gene for C-regulatory
protein in insect forms through transgenic parasites conferred
resistance to C-mediated lysis. The mere expression of
C-regulatory genes only in the metacyclic form might explain
the acquired resistance to serum lysis, but other mechanisms
could be involved [34]. We have found a novel C2 receptor,
CRIT, expressed in infective forms of the Y and Colombiana
strains ofT. cruzi, providing themwith resistance to C-mediated
lysis by NHS. The CRIT gene is highly similar to the gene de-
scribed in Schistosoma species andmammals [16]. CRIT in the Y
strain possesses the N-terminal ed1, reported to bind to C2 and
block the CP and the LP, and 3 transmembrane regions that
could be involved in membrane insertion. The gene sequences
obtained from the T. cruzi Cl Brener, Colombiana, and Dm28c
strains are highly homologous to that of the Y strain, with 88%,
90%, and 98% identity, respectively.
Overexpression of the Y strain CRIT gene in the C-sensitive
epimastigote forms resulted in transgenic epimastigote forms
being better able to resist C-mediated lysis. The level of lysis,
compared with that for wild-type parasites, decreased within the
firstminutes, showing that CRIT blocks the propagation of theC
cascade. This effect resembles metacyclic trypomastigote resis-
tance to C at the first contact in vertebrate hosts. Interestingly, in
the presence of AP alone, the degrees of lysis were similar in
epimastigotes overexpressing CRIT and in wild-type parasites,
indicating that CRIT inhibits specifically the CP and the LP, as
was described in Schistosoma species and their hosts. The expres-
sion of the class II CRIT gene of the Y strain in the T. cruzi
Colombiana strain conferred resistance toC lysis, indicating that
the gene is functional in the class I strain.
A broad set of virulence factors and invasion-associated mol-
ecules has been studied by different groups searching for quali-
tative and/or quantitative differences among T. cruzi class I and
II strains [18]. The phenomenon of the bipolar biological behav-
ior between classes associated with differentially expressed anti-
gens has not been interpreted convincingly. In this work, we
have seen differences at the level of C resistance between Colom-
biana (a class I strain) andY (a class II strain) and foundCRIT, at
the protein level, to be expressed differentially in the Y strain.
The lack of an effective vaccine or chemotherapeutic treatment
that protects the human host against trypanosomatid invasion
makes it especially important to understand the molecular basis
of the differences in C activation between class I and II strains
and thereby, it is hoped, to find putative new targets to control
the disease. The characterization of CRIT, a novel C-inhibiting
protein, could be key to elaborating a new chemotherapeutic or
vaccine-based strategy and to understanding the biological dif-
ferences between class I and II strains.
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